• Citer

TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer.

par Moretti, Erica;Desmedt, Christine ;Biagioni, Chiara;Regan, Meredith M;Oakman, Catherine;Larsimont, Denis ;Galardi, Francesca;Piccart-Gebhart, Martine ;Sotiriou, Christos ;Rimm, David D.L.;Di Leo, Angelo
Référence Future oncology, 9, 10, page (1477-1487)
Publication Publié, 2013-10

Article révisé par les pairs

• Détails
• Contenu

Résumé :

Anthracyclines are commonly used in breast cancer, although they lack validated predictive biomarkers. We explored the interaction between TOP2A protein by quantitative immunofluorescence (QIF) and anthracycline sensitivity.